```
cannabis_handbook_psychopharmacology.txt

Cannabis constituents: >100 phytocannabinoids (ElSohly & Gul, Ch. 1); <12 pharmacologically
investigated (Russo 2011).  Plant Growth Stages: Seedling (young, vulnerable), Vegetative (leaf/stem
growth), Flowering (bud production). Each stage has unique environmental/nutritional needs (Potter, Ch. 4).
Δ9-THC: Activates CB1 & CB2 receptors (Pertwee & Cascio, Ch. 6); partial agonist (Pertwee 1997,
1999); agonist/antagonist/inverse agonist (Sim et al. 1996; Patel & Hillard 2006). Targets noncannabinoid
receptors/channels (De Petrocellis et al. 2008, 2011; McHugh et al. 2012).
Δ8-THC: CB1/CB2 partial agonist (Matsuda et al. 1990; Martin et al. 1993).
CBN: Low-potency CB1 agonist/CB2 inverse agonist (MacLennan et al. 1998; Pertwee 1999).
Δ9-THCV: CB2 partial agonist/CB1 antagonist (Bolognini et al. 2010; Pertwee et al. 2007); agonist at
high doses (Pertwee et al. 2007).
(E)-BCP: CB2 agonist (Gertsch et al. 2008).

Nine nonpsychotropic phytocannabinoids (Cascio & Pertwee, Ch. 7): CBC, CBD, CBDV, CBDA, CBG,
CBGV, CBGA, THCA, THCVA.  Target TRP channels, PPARγ, GPR55, FAAH, MAGL (De Petrocellis et al.
2008, 2011, 2012). CBD:  5-HT1A agonist (Russo et al. 2005); adenosine uptake inhibitor (Carrier et al.
2006); neuroprotective (Fernández-Ruiz et al. 2012).  CBDA: 5-HT1A agonist (Bolognini et al. 2013). CBG:
α2-adrenoceptor agonist (Cascio et al. 2010); 5-HT1A antagonist (Rock et al. 2011). CBG and THCV: TRPM8
antagonist (De Petrocellis et al. 2010).

Phytocannabinoids and neurotransmission (Szabo, Ch. 8): Δ9-THC inhibits glutamatergic and GABAergic
synaptic transmission (Kelley & Thayer 2004; Shen & Thayer 1999; Laaris et al. 2010). CB1 receptor
activation, pre-synaptic inhibition (Castillo et al. 2012).  CBD: inhibits hippocampal glutamatergic
synaptic transmission (Ledgerwood et al. 2011). CB2 receptor role unclear (Atwood et al. 2012).
Δ9-THCV: antagonizes cannabinoid CB1 receptor (Ma et al. 2008; Thomas et al. 2005). CBG: α2-adrenoceptor agonist (Cascio et al. 2010). Cannabidiol antagonizes GPR55 (Sylantyev et al. 2013).

Phytocannabinoids and addiction (Gardner, Ch. 9): THC induces reward/positive reinforcement, withdrawal
dysphoria/negative reinforcement (Gardner 2011). Low dependence incidence (Abel 1980). CBD/THCV
potential anti-addictive efficacy (Ren et al. 2009; Thomas et al. 2005).

Phytocannabinoids and anxiety/mood/endocrine (Patel et al., Ch. 10): THC: biphasic anxiety effects
(Patel & Hillard 2006); HPA axis effects (D’Souza et al. 2004). CBD: antianxiety, antidepressant (Bergamaschi
et al. 2011; Zanelati et al. 2010); potential for anxiety disorders.

Phytocannabinoids and cardiovascular (O’Sullivan, Ch. 11): THC: tachycardia in humans (Benowitz et al.
1975); complex, species-dependent effects in animals. CBD: minimal cardiovascular effects. Targets
TRP channels, CB1/CB2 receptors, and PPARγ (O’Sullivan et al. 2005, 2009).

Phytocannabinoids and gastrointestinal (Duncan & Izzo, Ch. 12): THC/CBN: CB1-mediated inhibition of
motility; antisecretory (Izzo et al. 2000, 2003; Krowicki et al. 1999). CBD/CBC: normalize motility in
inflammation (Capasso et al. 2008; Izzo et al. 2012).  Antiproliferative (Ligresti et al. 2006).

Phytocannabinoids and reproduction (Stuart et al., Ch. 13): THC: impairs rodent sexual function; conflicting effects on human sexual function and fertility (Gorzalka et al. 2010). Adverse impacts on pregnancy
outcomes (Hayatbakhsh et al. 2012; Fried et al. 2003).  Effects on HPG axis (Bradshaw et al. 2006).  CB
receptors in reproductive tracts (Maccarrone 2009).

Phytocannabinoids and immune (Cabral et al., Ch. 14): THC: suppresses Th1 responses; CB2 receptor
involvement (Newton et al. 2009). CBD: shifts Th1/Th2 balance; non-cannabinoid receptor
involvement (Carrier et al. 2006; Weiss et al. 2006). Alters NK cell function (Klein et al. 1998).

Non-phytocannabinoid constituents (McPartland & Russo, Ch. 15): Terpenoids (e.g., β-caryophyllene,
limonene, linalool, α-pinene); flavonoids (e.g., quercetin, apigenin, cannaflavin A). Synergy with
phytocannabinoids (Russo 2011).

Cannabinoid pharmacokinetics/forensics (Huestis & Smith, Ch. 16): THC: Rapid absorption (smoked),
slower (oral); extensive first-pass metabolism (oral); long detection times (blood, urine, hair, OF) in
chronic users.  CBD: high bioavailability (smoked); slower (oral); significant first-pass metabolism (oral).
THCCOOH: major metabolite in urine.

References:  References from all chapters cited above are also applicable.

```